CA2058443A1 - Treating Disorders by Application of Insulin-Like Growth Factors and Analogs - Google Patents
Treating Disorders by Application of Insulin-Like Growth Factors and AnalogsInfo
- Publication number
- CA2058443A1 CA2058443A1 CA2058443A CA2058443A CA2058443A1 CA 2058443 A1 CA2058443 A1 CA 2058443A1 CA 2058443 A CA2058443 A CA 2058443A CA 2058443 A CA2058443 A CA 2058443A CA 2058443 A1 CA2058443 A1 CA 2058443A1
- Authority
- CA
- Canada
- Prior art keywords
- igf
- insulin
- analogs
- application
- growth factors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title abstract 4
- 102000013275 Somatomedins Human genes 0.000 title 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 3
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 abstract 3
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
Abstract
A method of enhancing the survival of neuronal cells in a mammal, the cells being at risk of dying, the method comprising administering to the mammal an effective amount of at least one of the following substances: IGF-I; a functional derivative of IGF-I; IGF-II; or a functional derivative of IGF-II, provided that if IGF-I or IGF-II is administered, NGF or a functional derivative of NGF is also administered.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/361,595 US5093317A (en) | 1989-06-05 | 1989-06-05 | Treating disorders by application of insulin-like growth factor |
US361,595 | 1989-06-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2058443A1 true CA2058443A1 (en) | 1990-12-06 |
CA2058443C CA2058443C (en) | 1998-11-03 |
Family
ID=23422661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002058443A Expired - Lifetime CA2058443C (en) | 1989-06-05 | 1990-06-05 | Treating disorders by application of insulin-like growth factors and analogs |
Country Status (10)
Country | Link |
---|---|
US (1) | US5093317A (en) |
EP (2) | EP0798000A3 (en) |
JP (1) | JPH0768138B2 (en) |
AT (1) | ATE156018T1 (en) |
CA (1) | CA2058443C (en) |
DE (1) | DE69031168T2 (en) |
DK (1) | DK0476044T3 (en) |
ES (1) | ES2106735T3 (en) |
HK (1) | HK1010989A1 (en) |
WO (1) | WO1990014838A1 (en) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6440928B1 (en) | 1988-12-06 | 2002-08-27 | Colorado State University Research Foundation | Method for treating diabetic neuropathy with NGF |
US6723699B1 (en) * | 1989-06-05 | 2004-04-20 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
US5652214A (en) * | 1989-06-05 | 1997-07-29 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
US6693076B1 (en) * | 1989-06-05 | 2004-02-17 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
US5792831A (en) * | 1990-02-08 | 1998-08-11 | Magainin Pharmaceuticals Inc. | Analogues of magainin peptides containing D-amino acids |
US5616562A (en) * | 1990-04-27 | 1997-04-01 | Murphy; Christopher J. | Methods and compositions using substance P to promote wound healing |
US5831001A (en) * | 1990-10-24 | 1998-11-03 | Allelix Biopharmaceuticals Inc. | Treatment of herpesvirus infection |
US5674849A (en) * | 1990-10-24 | 1997-10-07 | Allelix Biopharmaceuticals Inc. | Anti-viral compositions |
US5646120A (en) * | 1990-10-24 | 1997-07-08 | Allelix Biopharmaceuticals, Inc. | Peptide-based inhibitors of HIV replication |
US5633230A (en) * | 1990-10-24 | 1997-05-27 | Allelix Biopharmaceuticals, Inc. | Treatment of cytomegalovirus infection |
US6077823A (en) * | 1991-03-11 | 2000-06-20 | Creative Biomolecules, Inc. | Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury |
US6949505B1 (en) * | 1991-03-11 | 2005-09-27 | Curis, Inc. | Morphogen-induced dendritic growth |
US6800603B2 (en) | 1991-03-11 | 2004-10-05 | Curis, Inc. | Morphogen-induced neural cell adhesion |
US6495513B1 (en) | 1991-03-11 | 2002-12-17 | Curis, Inc. | Morphogen-enhanced survival and repair of neural cells |
SE9101341D0 (en) * | 1991-05-03 | 1991-05-03 | Kabi Pharmacia Ab | NEW MEDICINAL USE |
US5861373A (en) * | 1991-08-01 | 1999-01-19 | Genentech, Inc | IGF-1 to improve the neural condition |
DK0597033T3 (en) * | 1991-08-01 | 1997-06-02 | Genentech Inc | IGF-1 to improve the neural state |
US5298422A (en) * | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
US5925564A (en) * | 1991-11-06 | 1999-07-20 | Baylor College Of Medicine | Expression vector systems and method of use |
US6310040B1 (en) * | 1991-11-08 | 2001-10-30 | Cephalon, Inc. | Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs |
US6204240B1 (en) * | 1991-11-22 | 2001-03-20 | Genentech, Inc. | TGF-β1 to improve neural outcome |
CH684573A5 (en) * | 1991-11-25 | 1994-10-31 | Inst Molecular Biology Inc | The use of growth factors for producing a pharmaceutical composition for promoting growth of mammalian nerves |
US5281582A (en) * | 1992-02-27 | 1994-01-25 | Alliance Pharmaceuticals, Corp. | Serum growth factor |
WO1993023067A1 (en) * | 1992-05-08 | 1993-11-25 | Thomas Jefferson University | Igf-1 analogs |
ES2140463T3 (en) * | 1992-06-12 | 2000-03-01 | Cephalon Inc | PREVENTION AND TREATMENT OF PERIPHERAL NEUROPATHY. |
US20070078089A1 (en) * | 1992-07-06 | 2007-04-05 | Ishii Douglas N | Method for effecting changes in the central nervous system by administration of IGF-I or IGF-II |
AU6169894A (en) * | 1993-02-08 | 1994-08-29 | Syntex-Synergen Neuroscience Joint Venture, The | Methods for treating amyotrophic lateral sclerosis with cntf |
EP0729361A4 (en) * | 1993-11-15 | 1996-11-06 | Celtrix Pharma | Method of treating neurological disorders |
AU1439095A (en) * | 1993-12-15 | 1995-07-03 | Thomas Jefferson University | Igf-1 analogs |
US5629286A (en) * | 1994-03-31 | 1997-05-13 | Brewitt; Barbara | Homeopathic dilutions of growth factors |
US5444047A (en) * | 1994-06-16 | 1995-08-22 | Dipasquale; Gene | Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I |
US5716614A (en) * | 1994-08-05 | 1998-02-10 | Molecular/Structural Biotechnologies, Inc. | Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier |
US5712249A (en) * | 1994-09-08 | 1998-01-27 | Ciba-Geigy Corporation | Use of insulin-like growth factors I and II for inhibition of inflammatory response |
US5650496A (en) * | 1995-04-14 | 1997-07-22 | Cephalon, Inc. | IGF-I purification process |
US6756484B1 (en) | 1995-04-14 | 2004-06-29 | Cephalon, Inc. | IGF-I purification process |
US5741776A (en) * | 1995-05-22 | 1998-04-21 | Genentech, Inc. | Method of administration of IGF-I |
US5565428A (en) * | 1995-05-22 | 1996-10-15 | Genentech, Inc. | Method of administration of IGF-I |
EP0766966A3 (en) * | 1995-09-08 | 2001-02-28 | Eli Lilly And Company | Method of treating insulin resistance |
WO1997011959A1 (en) * | 1995-09-29 | 1997-04-03 | Receptron, Inc. | Biologically active mhc peptides having a repeated amino acid sequence motif |
ATE236652T1 (en) * | 1995-12-13 | 2003-04-15 | Aurogen Inc | IGF-I AND -II FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES |
US5798715A (en) * | 1996-06-28 | 1998-08-25 | Saperstone; Dorothy Luhr | Method and device for accessing remote control functions |
US6025368A (en) * | 1997-02-25 | 2000-02-15 | Celtrix Pharmaceuticals, Inc. | Method for treating the symptoms of chronic stress-related disorders using IGF |
US6015786A (en) | 1997-02-25 | 2000-01-18 | Celtrix Pharmaceuticals, Inc. | Method for increasing sex steroid levels using IGF or IGF/IGFBP-3 |
US6514937B1 (en) | 1997-02-25 | 2003-02-04 | Celtrix Pharmaceuticals, Inc. | Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3 |
US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
US6420518B1 (en) | 1997-04-04 | 2002-07-16 | Genetech, Inc. | Insulin-like growth factor agonist molecules |
WO1998052574A1 (en) | 1997-05-22 | 1998-11-26 | Cephalon, Inc. | Vitamin d analogues and their neuronal effects |
US6747003B1 (en) * | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6693075B1 (en) * | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US7247708B2 (en) * | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
ES2146530B1 (en) * | 1997-12-26 | 2001-04-16 | Consejo Superior Investigacion | USE OF THE IGF-I GROWTH FACTOR IN THE MANUFACTURE OF USEFUL COMPOSITIONS IN THE TREATMENT OF CEREBELAR ATAXY. |
US7118752B2 (en) * | 1998-07-22 | 2006-10-10 | University Of Connecticut | Compositions and methods for inhibiting the proliferation and invasiveness of malignant cells comprising E-domain peptides of IGF-I |
US6358916B1 (en) | 1998-07-22 | 2002-03-19 | Thomas T. Chen | Biological activity of IGF-I E domain peptide |
US7700353B2 (en) * | 1998-07-22 | 2010-04-20 | E-P Therapeutics, Inc. | Compositions and methods for inducing apoptosis in tumor cells |
CA2339833A1 (en) * | 1998-08-11 | 2000-02-24 | Sumitomo Pharmaceuticals Company Limited | Blood sugar level controlling agent |
CA2356109C (en) * | 1999-01-06 | 2008-04-22 | Genentech, Inc. | Insulin-like growth factor (igf) i mutant variants |
RU2278123C2 (en) * | 2000-02-11 | 2006-06-20 | Максиджен Холдингз Лтд. | Molecules similar to factor vii or viia |
US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US7812132B2 (en) | 2000-04-28 | 2010-10-12 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
AU2001263215A1 (en) | 2000-05-16 | 2001-11-26 | Genentech Inc. | Method for treating cartilage disorders |
US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
AU2001288443B2 (en) * | 2000-08-29 | 2007-06-07 | Aurogen Inc. | Method for treating the central nervous system by administration of IGF structural analogs |
WO2002032449A2 (en) * | 2000-10-13 | 2002-04-25 | Chiron Corporation | Method for treating ischemic events affecting the central nervous system |
US20030027755A1 (en) * | 2000-12-08 | 2003-02-06 | Jian Guan | Compositions and methods for the rescue of white matter |
EP1358209B1 (en) * | 2001-02-09 | 2006-12-27 | Genentech, Inc. | Crystallization of igf-1 |
US7605177B2 (en) * | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
US7041314B2 (en) | 2001-05-24 | 2006-05-09 | Neuren Pharmaceuticals Ltd. | GPE analogs and peptidominetics |
US20070004641A1 (en) * | 2001-05-24 | 2007-01-04 | Neuren Pharmaceuticals Limited | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate |
US7714020B2 (en) * | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
JP4253743B2 (en) * | 2001-12-03 | 2009-04-15 | 輝夫 西田 | Novel peptides and their pharmaceutical uses |
TWI305778B (en) * | 2001-12-03 | 2009-02-01 | Nishida Teruo | Peptides of an expressing unit for igf-i minimal activity and their pharmaceutical use |
ES2207387B1 (en) * | 2002-02-28 | 2005-07-16 | Consejo Sup. Investig. Cientificas | CHEMICAL COMPOSITION OF IGF-I FOR THE TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES. |
NZ536340A (en) * | 2002-04-30 | 2006-09-29 | Maxygen Holdings Ltd | Factor VII or VIIa polypeptide variants with N-glycosylation |
CA2840692A1 (en) * | 2002-09-30 | 2004-04-08 | Bayer Healthcare Llc | Fvii or fviia variants having increased clotting activity |
US20040176704A1 (en) * | 2003-03-04 | 2004-09-09 | Stevens Timothy A | Collection device adapted to accept cartridge for point of care system |
EP1608745B1 (en) * | 2003-03-20 | 2009-05-13 | Bayer HealthCare LLC | FVII OR FVIIa VARIANTS |
BRPI0411650A (en) * | 2003-06-19 | 2006-08-08 | Maxygen Holdings Ltd | polypeptide variant of factor vii (fvii) or factor viia (fviia), nucleotide sequence, expression vector, host cell, composition, use of a variant, and method for treating a mammal having a disease or disorder in which clot formation is desirable |
ES2788699T3 (en) * | 2004-08-30 | 2020-10-22 | Ipsen Biopharmaceuticals Inc | Procedure and device to diagnose and treat insulin-like growth factor deficiency disorders |
US20060069008A1 (en) * | 2004-09-28 | 2006-03-30 | Sanjay Mistry | Treatment of neurological deficits in the striatum or substanta nigra pars compacta |
US20060069009A1 (en) * | 2004-09-28 | 2006-03-30 | Messina Darin J | Treatment of neurological deficits in the striatum or substanta nigra pars compacta |
US20090012499A1 (en) * | 2005-02-08 | 2009-01-08 | Japan As Rep. By Pres. Of Nat. Cardiovascular Ctr. | Novel method for treating chronic severe heart failure by using insulin-like growth factor-1 (igf-1) |
WO2006097682A1 (en) * | 2005-03-18 | 2006-09-21 | Ucl Business Plc | Mechano growth factor peptides and their use |
CL2007002502A1 (en) * | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | VARIANTS OF THE SIMILAR GROWTH FACTOR TO HUMAN INSULIN-1 (IGF-1) PEGILATED IN LISIN; METHOD OF PRODUCTION; FUSION PROTEIN THAT UNDERSTANDS IT; AND ITS USE TO TREAT ALZHEIMER'S DISEASE. |
ES2322685B2 (en) * | 2006-11-21 | 2010-03-15 | Universidad De Malaga | USE OF LOW DOSE OF IGF-II IN AGING FOR ITS NEUROPROTECTORS AND HEPATOPROTECTORS EFFECTS. |
AU2008262387A1 (en) * | 2007-06-08 | 2008-12-18 | Massachusetts Institute Of Technology | IGF for the treatment of Rett Syndrome and synaptic disorders |
RU2010144014A (en) * | 2008-04-03 | 2012-05-27 | Ф. Хоффманн-Ля Рош Аг (Ch) | APPLICATION OF PEGILIATED IGF-I OPTIONS FOR TREATMENT OF NEUROMUSCULAR DISORDERS |
TWI541020B (en) | 2008-04-17 | 2016-07-11 | 巴克斯歐塔公司 | Biologically active peptides |
US9750769B2 (en) | 2014-10-20 | 2017-09-05 | Neuralstem, Inc. | Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof |
US20180200301A1 (en) * | 2015-05-21 | 2018-07-19 | Shanghai Institutes For Biological Sciences Chinese Academy Of Sciences | Low-Oxygen-Treated Mesenchymal Stem Cell and Use Thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4341762A (en) * | 1981-04-07 | 1982-07-27 | Haast William E | Use of snake venoms for treatment of neurological and related disorders |
JPS5965058A (en) * | 1982-10-05 | 1984-04-13 | Daiichi Rajio Isotope Kenkyusho:Kk | Heneicosapeptide |
US4699875A (en) * | 1982-11-24 | 1987-10-13 | Baylor College Of Medicine | Diagnosis of amyotrophic lateral sclerosis by neurotrophic factors |
US4511390A (en) * | 1983-06-10 | 1985-04-16 | E. I. Du Pont De Nemours And Company | Aralkylcarbamoyl peptide alcohols |
WO1988001693A1 (en) * | 1986-09-05 | 1988-03-10 | Young Niels O | Magnet ball pump |
US4783524A (en) * | 1985-09-17 | 1988-11-08 | Monsanto Company | Growth factors |
SE8505920D0 (en) * | 1985-12-13 | 1985-12-13 | Kabigen Ab | NEW PROTEIN AND ITS USE |
US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4751645A (en) * | 1986-08-12 | 1988-06-14 | Abrams William R | Method for sonic analysis of an anomaly in a seafloor topographic representation |
GB8624560D0 (en) * | 1986-10-14 | 1986-11-19 | Bp Chem Int Ltd | Polymer polyols |
JPS63196524A (en) * | 1987-02-10 | 1988-08-15 | Wakunaga Pharmaceut Co Ltd | Carcinostatic action adjuster of transmucosal absorption type |
DE3851776T2 (en) * | 1987-04-28 | 1995-05-04 | Boehringer Mannheim Gmbh | Use of IGF-II for the treatment of bone diseases. |
US5004697A (en) * | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
SE8703625D0 (en) * | 1987-09-18 | 1987-09-18 | Kabivitrum Ab | NEW MEDICAL USE |
WO1990003166A2 (en) * | 1988-09-27 | 1990-04-05 | The Health Foundation Limited | Method and composition for the treatment of burns |
WO1991002067A1 (en) * | 1989-07-27 | 1991-02-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Regulation of nerve growth factor synthesis in the central nervous system |
-
1989
- 1989-06-05 US US07/361,595 patent/US5093317A/en not_active Expired - Lifetime
-
1990
- 1990-06-05 AT AT90909874T patent/ATE156018T1/en not_active IP Right Cessation
- 1990-06-05 DE DE69031168T patent/DE69031168T2/en not_active Expired - Lifetime
- 1990-06-05 EP EP97200539A patent/EP0798000A3/en not_active Withdrawn
- 1990-06-05 DK DK90909874.1T patent/DK0476044T3/en active
- 1990-06-05 WO PCT/US1990/003166 patent/WO1990014838A1/en active IP Right Grant
- 1990-06-05 JP JP2509846A patent/JPH0768138B2/en not_active Expired - Lifetime
- 1990-06-05 EP EP90909874A patent/EP0476044B1/en not_active Expired - Lifetime
- 1990-06-05 CA CA002058443A patent/CA2058443C/en not_active Expired - Lifetime
- 1990-06-05 ES ES90909874T patent/ES2106735T3/en not_active Expired - Lifetime
-
1998
- 1998-11-16 HK HK98112043A patent/HK1010989A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US5093317A (en) | 1992-03-03 |
JPH0768138B2 (en) | 1995-07-26 |
JPH04507240A (en) | 1992-12-17 |
EP0798000A2 (en) | 1997-10-01 |
EP0476044A1 (en) | 1992-03-25 |
DE69031168D1 (en) | 1997-09-04 |
EP0476044B1 (en) | 1997-07-30 |
EP0798000A3 (en) | 1998-01-14 |
EP0476044A4 (en) | 1992-07-01 |
DE69031168T2 (en) | 1997-12-04 |
HK1010989A1 (en) | 1999-07-02 |
ATE156018T1 (en) | 1997-08-15 |
CA2058443C (en) | 1998-11-03 |
DK0476044T3 (en) | 1997-11-17 |
WO1990014838A1 (en) | 1990-12-13 |
ES2106735T3 (en) | 1997-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2058443A1 (en) | Treating Disorders by Application of Insulin-Like Growth Factors and Analogs | |
CA2122340A1 (en) | Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs | |
GR3007092T3 (en) | ||
GR3002659T3 (en) | Pharmaceutical composition for treating inflammation in the eye | |
IE862543L (en) | Pharmaceutical compositions | |
AU549846B2 (en) | Extraocular methof of treating the eye with liquid perfluorocarbons | |
PH24867A (en) | A method of treating conditions associated with photodamaged skin by using pharmaceutical compositions containing p(22-(5,6,7,8 tetrahydro-5,5,8,8-tetramethyl-2-naphtyl)propenyl)phenylsulfone and derivatives thereof | |
AU2293888A (en) | Dosage form for treating cardiovascular diseases | |
EP0284409A3 (en) | Active specific immune suppression | |
ES8207217A1 (en) | Alpha-amylase inactivator, process for its preparation, composition containing said inactivator, and this inactivator for the regulation of the blood sugar level. | |
CA2088254A1 (en) | Treatment for hypercholesterolemia | |
ZA893482B (en) | Process for dyeing hair by the sequential treatment with metal ion containing composition and dye composition containing 5,6-dihydroxyindole-2-carboxylic acid | |
AU584611B2 (en) | Kit for use in the treatment of osteoporosis | |
AU587054B2 (en) | Novel pharmaceutical compositions intended to the treatment of neuropathies and insuring the nervous regeneration | |
MY107103A (en) | Contrast media. | |
CA2107914A1 (en) | Method to profile and treat abnormal cells | |
AU4399189A (en) | Improved red blood cell preservative solution | |
AU1926188A (en) | N-benzoyl-n'-2,5-dihalo-4-perfluoroalkoxyphenylureas, their preparation and use in the control of pests | |
EP0147185A3 (en) | Therapeutic use of cytidyl disphosphocholine to increase neuronal acetylcholine | |
BG50926A3 (en) | A process for increasing lactic parenchyma growth | |
EP0329043A3 (en) | Optically active rhodium-complexes of 3,4-bis(diarylphosphino)-pyrrolidines, and their use in the preparation of phosphinothricine by asymmetric hydrogenation | |
AU2431984A (en) | Shampoo Composition of Neostigmine or Pyridostigmine | |
ZA908570B (en) | Preparation of mixtures of cypermethrin or cyfluthrin isomers enriched in more active species | |
EP0144489A3 (en) | Cerebral and peripheral antihypoxidoticum | |
Szirmai et al. | Effect spectrum of acetylsalicylic acid. Compared to a combined preparation containing acetylsalicylic acid. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |